Ionis’s Olezarsen Data Meet Multiple Marks In Blockbuster sHTG Indication

 
• By Mandy Jackson
  
Olezarsen showed durability and efficacy across sHTG patient subgroups in Phase III trials (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Clinical Trials